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Introduction. Small intestine cancers are a difficult oncological problem. Lack of specific symptoms and difficulties 
with accessing the location even for advanced diagnostic techniques delay the diagnosis and implementation of 
appropriate treatment. 
Aim. Analysis of incidence, clinical symptoms, diagnostic methods and results of treatment of small intestine tumors 
in the material of the Maria Skłodowska-Curie Institute — Oncology Center (MSCI) in Warsaw. 
Material and method. A retrospective analysis of 54 patients undergoing surgery for small intestine tumor in the years 
2006–2015. The evaluated group consisted of 26 (48%) males, 28 (52%) females, median age was 63.5 ± 13.5 years 
(23–86). 
Results. In the study group 18 (33%) cases of sarcomas were found, including 16 (30%) cases of GIST. The remaining 
cases were diagnosed as: adenocarcinoma — 13 patients (24%), neuroendocrine tumor (NET) — 8 (15%), malignant 
melanoma — 6 (11%), lymphoma — 3 (6%) and benign tumors — 6 (11%). Symptoms included gastrointestinal 
bleeding (55.5%), abdominal pain (48%), weight loss (31.5%), nausea (30%), vomiting (24%), flatulence (24%), inte-
stinal passage disturbances (15%). In 70% of patients anemia was diagnosed, which in 33% required an average of 
4.5 packed red blood cells (PRBC) units (range 1–100) to be transfused before treatment. The test that led to diagnosis 
was in 26 (48%) cases computed tomography, in 8 (15%) cases capsule endoscopy and in 5 (9%) cases double-balloon 
enteroscopy. Partial resection of the small intestine with regional lymph nodes was performed in 38 patients (70%), 
local excision in 5 (9%) patients and anastomosis gastric pass in 4 (7%) patients. So far, 17 (31%) deaths have been 
reported in this group of patients. 5-year survival was 93.8% for sarcomas, 53.9% for SIC, 66.7% for GEP-NET. 
Conclusions. Partial resection of the small intestine remains the basic method of radical surgical treatment. Both 
diagnostics and treatment should be carried out in reference centers.
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Introduction
Small intestine tumors (SITs) are rare and represent abo-
ut 2% of malignant tumors of the gastrointestinal tract [1]. 
Low incidence, late, non-specific symptoms and technical 
diagnostic difficulties cause that they are most often dia-
gnosed in emergencies, such as gastrointestinal obstruction, 
gastrointestinal bleeding or peritonitis. In 2010, malignant 
SITs in Poland accounted for 0.5% of all cancers and the stan-
dardized incidence rate was 0.4/105 for men and 0.3/105 for 
women [1]. The incidence rates increase with age, reaching 
a peak in the eighth decade of life. In relation to the average 
for the European Union countries, in 2010 the incidence in 
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Poland was twice as high [1]. In the USA, malignant SITs acco-
unt for 0.6% of all new cancer cases [2], with an incidence of 
2.3 per 100 000 people. The aim of the study was to analyze 
the prevalence of clinical symptoms, diagnostic methods 
and results of SIT treatment in MSCI material.
Material and method
In the years 2006–2015, 4463 patients were operated 
in the Department of Oncological Gastroenterology, Maria 
Skłodowska-Curie Institute — Oncology Center (MSCI) in 
Warsaw. The database of patients undergoing surgical tre-
atment was searched for diagnoses, choosing: duodenal, 
jejunum and ileum tumors, excluding ampulla of Vater’s 
tumors. Complete disease histories of 54 (1.2%) patients, 
including 26 men (48%), 28 women (52%), aged between 
23 and 86 years (median 63.5 ± 13.5), were extracted and 
analyzed. 
On the basis of the available data, the following para-
meters were analyzed: 
1. Type of neoplasm.
2. Dominant symptoms of the disease. 
3. Nutrition status. 
4. Anemia and transfusion of blood. 
5. The time from the first symptom to the beginning of 
treatment. 
6. Imaging and endoscopic examinations performed. 
7. The type of examination leading to the diagnosis. 
8. Type and scope of surgery. 
9. Postoperative complications. 
10. Duration of hospitalization. 
11. Disease-free survival time.
Results
Characteristics of the tumor
Among 54 SITs, 48 (89%) were malignant and 6 (11%) 
were benign lesions. Among cancers 6 (11%) metastatic 
tumors (metastases of melanoma) were found. Out of 42 pri-
mary malignant tumors, 18 (33%) sarcomas were repor-
ted, including 16 (30%) GISTs, 13 (24%) adenocarcinomas, 
8 (15%) neuroendocrine tumors and 3 (5%) lymphomas. 
Among 6 benign lesions, two angiomas were diagnosed 
histopathologially, one lipoma, one adenoma, one myoma 
and one muscle and one Brunner’s gland hamartoma — 
an extremely rare type of tumor representing only 5% of 
duodenal tumors. The most frequent SITs were located in 
duodenum 19 (36%), jejunum 18 (33%) and ileum 17 (32%), 
(Tab. I).
Symptomatology
The most frequently observed symptoms were gas-
trointestinal bleeding in 30 (55.5%) patients and recurrent 
abdominal pain in 26 (48%) cases. Less frequent were: 
weight loss (31.5%), nausea (30%), vomiting (13%), flatu-
lence (24%), recurrent symptoms of obstruction (15%). The 
most common symptom that initiated the diagnosis was 
gastrointestinal bleeding — 27 (50%) cases. In 19 (35%) 
patients bleeding and in 5 (9%) patients pain were the only 
symptoms of the disease. The remaining patients (56%) 
presented more than one symptom. The time elapsed from 
the first symptoms to surgery ranged from 0 to 2190 days 
(median 90 ± 379.56 days). In four cases (7%), the disease 
remained asymptomatic, and in one patient (2%) the first 
symptom was gastrointestinal perforation leading to an 
urgent surgical treatment. 
Pain, nausea and weight loss are symptoms presented in 
the vast majority of cases in patients with primary malignant 
SITs and metastatic tumors. In patients with benign lesions, 
bleeding to the gastrointestinal tract was more frequent, 
resulting in anemia, often requiring repeated transfusion of 
blood products. Characteristics of symptoms are presented 
in Table II.
Diagnostics
Most of the tumors were diagnosed by radiological ima-
ging and endoscopy. Only in 2 (4%) cases the diagnosis was 
made during laparotomy. Computed tomography (CT) was 
the most frequent examination leading to the diagnosis of 
SIT, which was decisive for the further treatment in 26 (48%) 
cases. Capsule endoscopy (CE) turned out to be the basic 
examination in 8 (15%), double-balloon endoscopy (DBE) in 
5 (9%) and gastroscopy in 5 (9%) patients. Endoscopic ultra-
sound (EUS) showed the presence of SIT in 3 (5%) patients, 
positron emission tomography (PET CT) in one (2%), (Tab. III).
The results of the laboratory tests showed a decrease 
in hemoglobin levels, of which 23 (43%) required trans-
fusion of packed red blood cell (PRBC) (range 1–100), me-
dian 4 ± 19.12. The highest number of PRBC transfusions 
Table I. Characteristics of lesions
Type of tumor n = 54 (%)
Malignant 48 (89%)
Benign 6 (11%)
Histopathological type
Sarcoma 18 (33%)
Adenocarcinoma 13 (24%)
GEP-NET 8 (15%)
Melanoma 6 (11%)
Lymphoma 3 (5%)
Benign 6 (11%)
Location of the tumor
Duodenum 19 (36%)
Caecum 18 (33%)
Ileum 17 (32%)
GEP-NET — gastroenteropancreatic neuroendocrine tumors
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was observed in the group of patients with benign tumors, 
8–100 individuals, median 19 ± 42.3. In patients with primary 
malignant SIT, relatively small volumes of blood products 
were transfused compared to patients with benign tumors, 
1–14 units, median 2 ± 2.5. In other patients, no significant 
changes were observed in the routinely determined com-
plete blood count, clotting parameters and concentration of 
electrolytes. The risk of PRBC transfusion was also assessed, 
depending on the histopathological type of cancer. This 
type of treatment required 7 (54%) patients with cancer, 7 
(39%) with sarcoma, 1 (12.5%) with GEP-NET, 5 (83%) with 
melanoma and 2 (67%) with lymphoma.
Treatment 
Out of 54 surgeries, 16 (30%) were performed on emer-
gency basis, of which 10 patients (18%) were bleeding to 
the gastrointestinal tract. This symptom occurred in two 
(4%) patients with SIC, three (5.5%) patients with GIST, one 
(2%) patient with angioma, one (2%) patient with Brunner’s 
gland hamartoma and three (5.5%) patients with melanoma 
metastasis. In 3 (5.5%) cases, the urgent indication for sur-
gery were the symptoms of obstruction, which were caused 
by SIC, GEP-NET and GIST, respectively. In one (2%) patient 
bleeding and obstruction occurred at the same time and 
was caused by poorly differentiated SIC. In the remaining 2 
(4%) patients the indication for urgent surgical treatment 
was acute abdominal pain, and in one (2%) patient with GIST 
there was a perforation of the gastrointestinal tract. Sche-
duled operations were performed in 38 (70%) patients, after 
discussion of indications at multidisciplinary team meetings.
The dominant type of SIT surgeries was small intestine 
partial resection (SIPR). In the discussed group of patients, it 
was performed in 39 (72%) patients. In four cases the scope 
of the surgery was extended by left hemicolectomy due to 
Table II. Symptomatology of small intestine tumors
Symptom Frequency n (%)
Malignant tumors
n = 48
Benign tumors
n = 6
Total
n = 54
Initial symptom
GB 24 (50%) 6 (100%) 30 (56%) 27 (50%)
Abdominal pain 25 (52%) 1 (17%) 26 (48%) 16 (30%)
Weight loss 17 (35%) – 17 (32%) –
Nausea 16 (33%) – 16 (30%) –
Vomiting 13 (27%) – 13 (24%) –
Flatulence 12 (25%) 1 (17%) 13 (24%) –
Obstruction 8 (17%) – 8 (15%) 6 (11%)
GB — gastrointestinal bleeding
Table III. Diagnostics of small intestine tumors
Test name Number of tests carried out
Malignant tumors
n = 48 (%)
Benign tumors
n = 6 (%)
Total
n = 54 (%)
Critical test*
Computed tomography 45 (94%) 5 (83%) 50 (93%) 26 (48%)
Gastroscopy 38 (79%) 6 (100%) 44 (81%) 5 (9%)
Colonoscopy 31 (64%) 6 (100%) 37 (68%) 1 (2%)
Ultrasonography 22 (45%) 5 (83%) 27 (50%) 2 (4%)
EUS 8 (17%) – 8 (15%) 3 (5%)
Capsule endoscopy 9 (19%) 4 (67%) 13 (24%) 8 (15%)
DBE 7 (15%) 4 (67%) 11 (20%) 5 (9%)
GP 12 (25%) 2 (33%) 14 (26%) 1 (2%)
Scintigraphy 6 (12.5%) 2 (33%) 8 (15%) 1 (2%)
Diagnostic laparotomy 1 (2%) 1 (17%) 2 (4%) 2 (4%)
Fecal occult blood 12 (25%) 2 (33%) 14 (5 positive) –
* Critical test — the investigation that resulted in the diagnosis
EUS — endoscopic ultrasound; DBE — double-balloon enteroscopy; GB — gastrointestinal passage 
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cancer infiltrating the transverse mesentery in the area of 
the spleen fold, partial resection of the colon due to cancer 
infiltrating the transverse wall, scheduled extirpation of 
uterus myomatosus during primary surgery due to GIST of 
the ileum and adnexectomy due to GEP-NET with intraope-
rative suspicion of metastases to adnexa. In 4 (7%) patients 
pancreaticoduodenectomy using Whipple’s procedure (PD) 
was performed. In 5 (9%) patients the surgery was limited 
to local excision and one (2%) to right-hand hemicolectomy 
(HCD). In 4 (7%) cases tumors were considered as primarily 
non-resectional, which was associated with the use of pal-
liative management in the form of bypass anastomoses. In 
2 cases (4%) these lesions were located in the mesentery of 
the small intestine, while in 2 other patients they included 
successively the duodenum and the jejunum as well as the 
duodenum alone. One patient with jejunum angioma was 
qualified for diagnostic laparotomy, which was combined 
with intraoperative endoscopic examination (Tab. IV) 
Postoperative complications were observed in 7 (13%) 
patients, of which 3 (5.5%) had anastomotic leaks. Other 
cases of complications included damage to the ureter, in-
fection of the biliary tract, postoperative bleeding, biliary 
leak from the neck of the gall bladder after cholecystectomy. 
The duration of hospitalization ranged from 7 to 35 days, 
the median was 12 ± 5.37 days. Of the 54 procedures carried 
out, 43 (80%) were considered radical and 10 (18%) — pal-
liative. One surgery was of a diagnostic nature. 16 (30%) 
patients were qualified for complementary treatment. In 8 
(15%) patients with SIC FOLFOX and Mayo schemes based 
on fluorouracyl were applied, imatinib in 2 (4%) patients 
with GIST, CHOP in 2 patients with lymphoma, and CVD in 
1 patient with melanoma. Somatostatin analogues were 
used in 2 patients with GEP-NET, and in one etoposide and 
fluorouracyl. 
Survival
So far, 17 (31%) deaths have been reported in this group 
of patients. 5-year survival was 93.8% for sarcomas, 53.9% 
for SIC, 66.7% for GEP-NET, (Fig. 1).
Depending on the location of the tumor, the worst 
prognosis is for the duodenum tumors, where 5-year su-
rvival was 52.4%. These values are more favorable for the 
ileum and jejunum, which amounted to 83.3% and 91.7% 
respectively.
Table IV. Types of performed surgeries
Surgery type Number of tests carried out
Malignant tumors
n = 48
Benign tumors
n = 6
Total
n = 54
Complications
SIPR 36 (75%) 3 (50%) 39 (72%) 1 (2%)
PD 4 (8.5%) – 4 (7.5%) 4 (100%)
HCD 1 (2%) – 1 (2%)
Local excision 3 (6%) 2 (33%) 5 (9%) 2 (40%)
Bypass anastomosis 4 (8.5%) – 4 (7.5%)
Diagnostic laparotomy – 1 (17%) 1 (2%)
SIPR — small intestine partial resection; PD — pancreaticoduodenectomy; HCD — right hemicolectomy
Figure 1. Survival analysis for the most commonly diagnosed neoplasms
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Discussion
In the evaluated group the highest percentage of pa-
tients were GIST patients, followed by patients with adeno-
carcinoma and GEP-NET. Similar data were presented after 
the analysis of a group of 57 Romanian patients [3], recor-
ding 42.1% patients with GIST, 33.3% with cancer, 14% with 
lymphoma and 3.5% with GEP-NET. Other authors report the 
most cases of SIC, less frequently GIST and GEP-NET [4–8]. 
Researchers from China analyzed a group of 141 patients 
with median age 53.5, SIC occurred in 43.3% of cases, GIST 
in 19.8%, NET in 12.1%. Another analysis of 666 patients 
from China describes an even higher prevalence of SIC, i.e. 
87.5%. In this study only 8% of patients with GIST and 2.7% 
with GEP-NET were reported [9]. European publications 
based on a small number of patients confirm Asian data. In 
a Portuguese study from 2015, 28 patients were analyzed 
and the recorded data were: 39% — SIC, 21% — sarcomas, 
21% — lymphomas and 11% —GEP-NET [4]. In our opinion, 
this difference may be explained by the fact that the MSCI 
has no A&E department. Some authors suggest that SIC is 
much more likely to cause sudden, acute symptoms quali-
fying patients for hospital treatment [5]. In this case, the 
vast majority of patients are admitted to regional hospitals, 
where they are operated on an ad hoc basis. According 
to the quoted authors, the main location of the SIT is the 
duodenum (range 25–94%). There are slight statistical dif-
ferences between the jejunum and ileum (range 4.2–30.5% 
and 2.1–45%, respectively) [4–6, 9]. In our observations, SITs 
were most often located in the duodenum (36%), jejunum 
(33%) and ileum (32%), which corresponds to the data from 
the literature. The assessment of the tumor location depen-
ding on the histopathological type also coincides with the 
global data. In the study describing the American database 
of 67 843 patients diagnosed and treated in 1985–2005, the 
main localization of cancer was duodenum (56%), while it 
was jejunum for sarcomas (25%), and ileum for GEP-NET 
and lymphomas (45% and 21%, respectively) [10]. In our 
material there were no significant differences in the location 
of cancers. 
The most frequent symptoms of SITs observed in li-
terature were pain (14–67%), gastrointestinal obstruction 
(3.9–50%), gastrointestinal bleeding (3.9–39%) [4–6, 9, 11, 
12]. Jaundice, fever, perforation, flatulence and diarrhea 
were described less frequently. The most frequent symptom 
in this study was bleeding (50%). The remaining results cor-
responded with the cited works. In 7% patients the disease 
remained asymptomatic. These ailments are non-specific 
and occur late, which postpones the onset of diagnosis 
and treatment [4–6, 9, 11, 12]. Some authors draw attention 
to the fact that the first ailment causing the beginning of 
diagnostics were obstruction and bleeding requiring urgent 
surgical intervention on emergency basis. The frequency of 
such a course may reach 40% [11].
SIT imaging in endoscopic examination is difficult and 
possible mainly in large centers with extensive diagnostic 
facilities. Within the range of classical gastroscopy and co-
lonoscopy there are only tumors of the duodenum and 
a  fragment of the ileum directly before the caecum. The 
other SITs can rarely be located in this way. Only the use of 
CE and DBE allowed to show the lesions beyond the range 
of classic imaging equipment [13–17]. DBE, introduced in 
2001, was particularly helpful; it was the first to show the 
entire digestive tract in real time and to collect material 
for histopathological examination. Korean and Japanese 
studies emphasize the advantages of CE and DBE especially 
in comparison to CT [13–17]. Especially CE, additionally in 
combination with MRI or CT, is presented as the best dia-
gnostic method due to the accuracy, high sensitivity and 
good tolerance by the patient [13–16]. In addition, the DBE 
allows the use of a tattoo to mark the location of the tumor, 
which may be of great importance during resection surgery, 
as well as the possibility to stop bleeding temporarily or final 
treatment of small SITs [13–17]. In the conclusions of the 
meta-analysis of 5 studies (1154 patients in total), both CE in 
combination with MRI or CT as well as DBE, the comparable 
sensitivity of the study and the percentage of undetected 
lesions were determined [13–17]. CT is still a good method of 
depicting SITs of a diameter larger than 10 mm, however, it 
does not allow for their precise location. Many authors place 
CT as the main diagnostic test due to its easy availability 
and relatively high sensitivity. It seems that the best choice 
for the most accurate diagnosis and imaging of SIT is to use 
a combination of CT and endoscopic methods [13–17]. In 
Poland, the limited availability of CE and DBE means that 
CT remains the key test.
A vast majority of authors point out that radical surgical 
treatment remains the only right course of action in the 
case of SIT. The most frequent operation is SIPR (53–68%) 
[4–8]. In this study 20–76% of patients were qualified for 
complementary treatment. The group most often qualified 
for chemotherapy were patients with SIC [9, 11, 18]. Recent 
data from the National Cancer Register indicate that the 
1-year survival rate is 65.3% in men and 62.7% in women, 
and 5-yearly survival rates are 45.1% in men and 49.3% 
in women respectively [2]. Mortality due to SIT in Poland 
in 2010 was 0.4 and is identical to the data from the U.S. 
National Cancer Institute [1]. 
Summary
The most common clinical symptom of SIT is gastro-
intestinal bleeding requiring transfusion of many blood 
units. CT is the most common examination deciding about 
the diagnosis. 
Surgical treatment remains the only effective way to 
cure patients. The most common procedure is SIPR. After 
5 years of surgery, 37 (68.5%) patients remain in follow-up.
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SITs remain a difficult oncological problem. Late, non-
-specific symptoms, slow tumor growth, occurrence in old 
age, the need to use difficult diagnostic techniques, results 
in a long time of diagnosis and appropriate treatment. The 
care of SIT patients should take place in centers of higher 
reference, with advanced diagnostic capabilities and expe-
rienced specialist staff. 
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